40 unchanged sentences
The claims in ToolGen’s patent application relate to a mammalian cell with a CRISPR/Cas system comprising a codon optimized nucleic acid encoding a Cas9 polypeptide with a nuclear localization signal and a single-molecule guide RNA that, together, are capable of forming a Cas9/RNA complex that mediates double stranded cleavage of a target nucleic acid sequence.
−Removed: On June 21, 2021, the PTAB declared two new patent interferences involving a pending U.S.
+Added: On June 21, 2021, the PTAB declared two new interferences involving a pending U.S.
patent application owned by Sigma-Aldrich (the “Sigma-Aldrich application”).
−Removed: One of the two new patent interferences is between the Sigma-Aldrich application and certain U.S.
+Added: One of the two new interferences is between the Sigma-Aldrich application and certain U.S.
patents and U.S.
patent applications that are co-owned by Broad and in-licensed by us.
−Removed: The second new patent interference is between the same Sigma-Aldrich application and the U.S.
+Added: The other Sigma interference is between the same Sigma-Aldrich application and the U.S.
patent applications that are co-owned by CVC.
36 unchanged sentences
Even if we are successful in any interference proceeding or other priority, inventorship, or validity disputes, it could result in substantial costs and be a distraction to our management and other employees.
−Removed: Exhibit Index
−Removed: Description of Exhibit
−Removed: Rule 13a-14(a) Certification of Principal Executive Officer
−Removed: Rule 13a-14(a) Certification of Principal Financial Officer
−Removed: Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C.
−Removed: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language):
−Removed: (i) Consolidated Balance Sheets (unaudited), (ii) Consolidated Statements of Operations (unaudited), (iii) Consolidated Statements of Comprehensive Loss (unaudited), (iv) Consolidated Statements of Stockholders’ Equity (unaudited), (v) Consolidated Statements of Cash Flows (unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags.
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL.
−Removed: * Filed herewith
−Removed: + The certifications furnished in Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
−Removed: Such certifications are not to be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates them by reference.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: EDITAS MEDICINE, INC.
−Removed: /s/ Michelle Robertson
−Removed: Michelle Robertson
−Removed: Chief Financial Officer
−Removed: (Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.